N/A

Average User
Rating

N/A

Average Analyst
Rating
stockTargetAdvisor

Very Bullish

Stock Target Advisor
Analysis

USD 0.08

0.00 (0.00)%

USD 8.59B

1.99M

N/A

N/A

Icon

MYL

Mylan N.V (USD)
COMMON STOCK | NSD
USD 0.08
0.00 0

N/A

Average User
Rating

N/A

Average Analyst
Rating
stockTargetAdvisor

Very Bullish

Stock Target Advisor
Analysis

USD 8.59B

N/A

USD 0.08

Mylan N.V Stock Forecast

N/A

Based on the Mylan N.V stock forecasts from 0 analysts, the average analyst target price for Mylan N.V is not available over the next 12 months. Mylan N.V’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Mylan N.V is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Mylan N.V’s stock price was USD 0.08. Mylan N.V’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Mylan N.V
No recent average analyst rating found for Mylan N.V

Company Overview

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredien...Read More

http://www.mylan.com

Building 4, Hatfield, United Kingdom, AL10 9UL

35,000

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

  • 1.47

  • N/A

  • 11.15

  • N/A

  • 47,144,965

  • USD 16.12

  • 46,489,413

  • USD 16.42

  • 0.91%

  • 11.05%

  • 90.50%

  • N/A

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Security Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Mylan N.V (Sector: Drug Manufacturers-Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD
PPD Inc 0.00 (0.00%) USD16.61B 47.04 21.58
VTRS
Viatris Inc +0.10 (+0.82%) USD14.42B 18.02 6.97
NBIX
Neurocrine Biosciences Inc -0.71 (-0.64%) USD10.41B 180.48 98.51
APHA
Tilray, Inc 0.00 (0.00%) USD6.86B 60.60 454.68
MNTA
Momenta Pharmaceuticals, Inc 0.00 (0.00%) USD6.24B N/A N/A
ALKS
Alkermes Plc +0.05 (+0.17%) USD4.73B N/A -72.85
ITCI
Intracellular Th -0.10 (-0.21%) USD4.45B N/A -14.58
LNTH
Lantheus Holdings Inc +1.14 (+1.98%) USD3.86B 36.91 16.96
EVO
Evotec SE ADR +0.10 (+1.03%) USD3.66B 508.00 -19.09
HCM
HUTCHMED DRC +0.73 (+4.05%) USD3.64B 17.69 -6.38

ETFs Containing MYL

Symbol Name Weight Mer Price(Change) Market Cap
GNRX
VanEck Vectors Generic Dr.. 4.43 % 0.55 % 0.00 (0.00%) USD3.35M

Frequently Asked Questions About MYL Stock

Stock Target Advisor's fundamental analysis for Mylan N.V's stock is Very Bullish.

Unfortunately we do not have enough data on MYL's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on MYL's stock to indicate what its average analyst target is.

MYL stock's Price/Earning ratio is 30.73. Based on this MYL may be a overvalued for its sector.

The last closing price of MYL's stock was USD 0.08.

The most recent market capitalization for MYL is USD 8.59B.

Unfortunately we do not have enough analyst data on MYL's stock to indicate whether its price will go up or not.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...